Ascletis Pharma hits near 4-month peak on weight-loss drug progress

Ascletis Pharma

09/12/2025 04:21

** Shares of Ascletis Pharma Inc 1672.HK jump 24% to HK$17.78, their highest level since Aug 18

** Stock set for biggest one-day pct gain since April 22

** Ascletis announces positive topline results in its 13-week Phase II study of ASC30, an oral GLP-1 obesity drug, in 125-participant U.S. trial

** "We are excited about the results from of our Phase II study which suggests a potential best-in-class profile of ASC30 for both weight loss and GI (gastrointestinal) tolerability" -  chairman Jinzi Jason

** Plans U.S. FDA submission, request End-of-Phase II meeting in 2026 Q1

** YTD, stock up 452%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))